Biospecimen Core
- Institution
- DANA-FARBER CANCER INST, MA
- Principal investigator
- Mark M. Pomerantz
- Funding
- $199K
- Duration
- 2023–2028
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY – BIOSPECIMEN CORE (CORE C) Acquisition and characterization of biospecimens linked with clinical data and the development of patient relevant preclinical models, are essential components for effective and impactful translational research. The Dana Farber/ Harvard Cancer Center (DF/HCC) Prostate SPORE Biospecimen Core (Core C) will maintain and expand a mature prostate cancer biorepository, including blood and tissue specimens, from a diverse group of prostate cancer patients across DF/HCC who have provided consent to our clinical database and biobank protocols. Core C will provide tissue specimens and vast pathology expertise to SPORE investigators including the evaluation of both human and mouse model tissues. Core C will maintain a database of clinical data on all consented patients, linked with standardized pathology review procedures and data collection. Core C will work closely with SPORE investigators and collaborators to provide interpretative and consultative pathology services, including stateoftheart molecular assays and imaging technologies developed at DF/HCC. Centralization of Core activities builds upon established infrastructure but does not replicate existing resources within the DF/HCC. Overall, Core C will greatly facilitate and accelerate translational research within the DF/HCC Prostate SPORE through the collection and integration of highly annotated biological material and associated clinical information.
LOADING MOONBASE SCORE
Questions for DANA-FARBER CANCER INST
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · Dana-Farber Cancer Inst51
HIV-1 Preintegration Trafficking and Nuclear Localization
Alan N. Engelman · $1.2M · 2003–2027
- NIH · Dana-Farber Cancer InstReviewed
Acupuncture for Chemothrapy-induced Peripheral Neuropathy Treatment (ACT) Trial
Ting Bao · $661K · 2023–2025
- NIH · Dana-Farber Cancer InstReviewed
DF/HCC Preclinical Translation-Focused Clinical Investigator to Bridge PDXNet and the ETCTN
Keith T Flaherty · $194K · 2014–2026